Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Denmark
  4. Nasdaq Copenhagen
  5. H. Lundbeck A/S
  6. News
  7. Summary
    LUN   DK0010287234

H. LUNDBECK A/S

(LUN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

H Lundbeck A/S : Transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated parties

05/26/2021 | 04:18am EDT

Valby, Denmark, 26 May 2021- H. Lundbeck A/S (Lundbeck) hereby publishes and reports transactions made by executives and persons closely associated with them with shares and linked securities in Lundbeck.

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Per Johan Luthman
2. Reason for the notification
a) Position/status Executive Vice President, Research & Development
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant,
auction platform, auctioneer or auction monitor
a) Name H. Lundbeck A/S
b) LEI code 5493006R4KC2OI5D3470
4 Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial
instrument, type of instrument

Identification code
SharesDK 0010287234
b) Nature of the transaction Purchase of shares
c) Price(s) and volume(s) Price(s) Volume(s)
200.10 2,439
d) Aggregated information
- Aggregated volume
- Price
e) Date of the transaction 2021-05-25
f) Place of the transaction NASDAQ Copenhagen XCSE

Persons under an obligation to report are defined as members of the Executive Management, members of the Board of Directors and other executives of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

  • spouse or cohabitant
  • dependent children
  • legal entities in which the executive has a controlling influence.
 

Lundbeck contacts

Investors:                                   

Media:

Palle Holm Olesen Juliane Lenzner
Vice President, Investor Relations Vice President, Corporate Communication
PALO@lundbeck.com JULZ@lundbeck.com
+45 30 83 24 26 +45 36 43 40 00
 

About H. Lundbeck A/S

H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY) is a global pharmaceutical company specialized in brain diseases. For more than 70 years, we have been at the forefront of neuroscience research. We are tirelessly dedicated to restoring brain health, so every person can be their best.

An estimated 700 million people worldwide are living with brain diseases and far too many suffer due to inadequate treatment, discrimination, a reduced number of working days, early retirement and other unnecessary consequences. Every day, we strive for improved treatment and a better life for people living with brain diseases - we call this Progress in Mind.

Read more at www.lundbeck.com/global/about-us/progress-in-mind. 

For additional information, we encourage you to visit our corporate site www.lundbeck.com and connect with us on Twitter at @Lundbeck and via LinkedIn.

H. Lundbeck A/S

Ottiliavej 9, 2500 Valby, Denmark

+45 3630 1311

info@lundbeck.com

https://news.cision.com/h--lundbeck-a-s/r/transactions-with-shares-and-linked-securities-in-h--lundbeck-a-s-made-by-executives-and-their-close,c3353759

https://mb.cision.com/Main/18215/3353759/1422764.pdf

(c) 2021 Cision. All rights reserved., source Press Releases - English

All news about H. LUNDBECK A/S
09/14HERANTIS PHARMA OYJ : Names Chairman of New Scientific Advisory Board
MT
08/18H LUNDBECK A/S : Drugmaker Lundbeck lowers sales outlook as generic competition ..
RE
08/18H LUNDBECK A/S : Lundbeck continues to deliver solid growth for strategic brands..
AQ
08/18H. Lundbeck A/S Reports Earnings Results for the Second Quarter Ended June 30..
CI
08/04H LUNDBECK A/S : Lundbeck enters strategic research collaboration with Rgenta Th..
PU
08/04Rgenta Therapeutics, Inc. Enters into a Collaboration with H. Lundbeck A/S
CI
07/22H LUNDBECK A/S : What do you mean brain health?
PU
07/01Denovo Biopharma LLC Announces In-Licenses Late-Stage Alzheimer's Disease Ass..
CI
06/15#1VOICESUMMIT : Partnering with the advocacy community to further brain health a..
PU
06/11H LUNDBECK A/S : Lundbeck CEO, Deborah Dunsire, warns that we could be on the br..
PU
More news
Analyst Recommendations on H. LUNDBECK A/S
More recommendations
Financials
Sales 2021 16 422 M 2 590 M 2 590 M
Net income 2021 1 453 M 229 M 229 M
Net Debt 2021 2 161 M 341 M 341 M
P/E ratio 2021 23,4x
Yield 2021 1,67%
Capitalization 33 818 M 5 337 M 5 334 M
EV / Sales 2021 2,19x
EV / Sales 2022 1,91x
Nbr of Employees 5 603
Free-Float 30,7%
Chart H. LUNDBECK A/S
Duration : Period :
H. Lundbeck A/S Technical Analysis Chart | LUN | DK0010287234 | MarketScreener
Technical analysis trends H. LUNDBECK A/S
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 15
Last Close Price 170,20 DKK
Average target price 229,60 DKK
Spread / Average Target 34,9%
EPS Revisions
Managers and Directors
Deborah L. Dunsire President & Chief Executive Officer
Anders G÷tzsche Chief Financial Officer & Executive Vice President
Lars S°ren Rasmussen Chairman
Lars Bang Executive VP-Supply Operations & Engineering
Johan Luthman EVP & Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
H. LUNDBECK A/S-18.49%5 337
JOHNSON & JOHNSON4.68%433 701
ROCHE HOLDING AG10.97%321 442
PFIZER, INC.20.81%246 078
NOVO NORDISK A/S50.80%232 556
ELI LILLY AND COMPANY36.28%208 604